Primary Site >> Pancreatic Cancer
Gene >> DPP4
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
|
Ref: Modulation of enzymatic activities during spontaneous and induced differentiation in a human pancreatic adenocarcinoma cell line CAPAN-1. PMID: 2543714 |
Ref: Bone marrow-derived progenitor cells could modulate pancreatic cancer tumorigenesis via peritumoral microenvironment in a rat model. PMID: 19544970 |
Ref: GLP1 and cancer: friend or foe? PMID: 22691625 |
Ref: The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes. PMID: 24126227 |
Ref: Hope and fear for new classes of type 2 diabetes drugs: is there preclinical evidence that incretin-based therapies alter pancreatic morphology? PMID: 24424288 Ref: The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. PMID: 24746233 |
Ref: Evaluation of Anti Cancer Effects of DPP-4 Inhibitors in Colon Cancer- An Invitro Study. PMID: 26816911 |
Ref: Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation. PMID: 26607297 Ref: GLP-1 mimetic drugs and the risk of exocrine pancreatic disease: Cell and animal studies. PMID: 26751948 Ref: Increased tissue and circulating levels of dipeptidyl peptidase-IV enzymatic activity in patients with pancreatic ductal adenocarcinoma. PMID: 27320722 Ref: Suppression of CD26 inhibits growth and metastasis of pancreatic cancer. PMID: 27718126 |
Ref: Vildagliptin loaded triangular DNA nanospheres coated with eudragit for oral delivery and better glycemic control in type 2 diabetes mellitus. PMID: 29145151 Ref: Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier. PMID: 29556215 |